Internal Medicine, Infectious Disease · Overland Park, KS
NPI
1740497122
Since 2007
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4601 W 109th St Ste 100
Overland Park, KS, 66211
Phone (816) 942-0540
Groups this clinician bills Medicare through
Medicare paid, 2024
$512K
52,611 services
Medicare patients, 2024
584
Average age 74
Drug cost, 2024
$389K
889 prescriptions
Company payments, 2025
$34.29
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Apoorv Y Kalra was code J0875 (injection, dalbavancin, 5 mg), 11,850 times for 37 patients. In total Apoorv Y Kalra billed 52,611 services in 33 codes, and Medicare paid $512K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-02-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0875 Injection, dalbavancin, 5 mg | Office | 11,850 | 37 | $12.14 | $144K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 6,930 | 13 | $8.71 | $60K |
| J0897 Injection, denosumab, 1 mg | Office | 3,660 | 53 | $21.04 | $77K |
| 99233 Hospital E&M - Subsequent | Facility | 558 | 263 | $89.65 | $50K |
| 99223 Hospital E&M - Initial | Facility | 357 | 319 | $127.40 | $45K |
| 96365 Intravenous Infusion, Hydration | Office | 252 | 73 | $46.02 | $12K |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 178 | 23 | $8.70 | $1,549 |
| 99214 Office E&M - Established | Office | 176 | 99 | $93.71 | $16K |
| 99232 Hospital E&M - Subsequent | Facility | 138 | 113 | $59.99 | $8,279 |
| 96401 Chemotherapy Administration | Office | 91 | 66 | $51.12 | $4,652 |
| 99213 Office E&M - Established | Office | 59 | 48 | $65.37 | $3,857 |
| 99222 Hospital E&M - Initial | Facility | 55 | 54 | $99.28 | $5,461 |
| 36415 Venipuncture Blood Collection | Office | 26 | 14 | $8.65 | $225 |
By year: 2022 $513K for 91,855 services; 2023 $363K for 91,165 services; 2024 $512K for 52,611 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 26 | 14 | $8.65 | $225 |
Medicare prescription drug claims, 2024
In 2024, the drug Apoorv Y Kalra prescribed most often to Medicare patients was Doxycycline Hyclate, with 81 prescriptions and refills. In total Apoorv Y Kalra wrote 889 Medicare prescriptions that cost $389K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Doxycycline Hyclate Generic | 81 | 95 | 18 | $2,226 |
| Cephalexin Generic | 71 | 80 | 20 | $1,315 |
| Ceftriaxone Ceftriaxone Sodium | 64 | 64 | 25 | $2,625 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 50 | 50 | 26 | $1,206 |
| Cefdinir Generic | 49 | 51 | 18 | $4,336 |
| Ertapenem Ertapenem Sodium | 49 | 49 | 18 | $21K |
| Doxycycline Monohydrate Generic | 45 | 61 | 18 | $1,532 |
| Daptomycin Generic | 42 | 42 | 15 | $15K |
| Amoxicillin Generic | 37 | 46 | 11 | $240 |
| Vancomycin Hcl Generic | 35 | 36 | 14 | $5,854 |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | 32 | 32 | Under 11 | $6,193 |
| Cefepime Hcl Generic | 25 | 25 | Under 11 | $10K |
| Caspofungin Acetate Generic | 23 | 23 | Under 11 | $17K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 21 | 21 | Under 11 | $76K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 20 | 20 | Under 11 | $88K |
Brand drugs: 78 claims; generic drugs: 811 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Apoorv Y Kalra $34.29 ($34.29 in general payments such as food, travel and fees) from 1 company. The largest payer was Insmed, Inc. with $34.29.
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. INSM | 2 | $34.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.